For the past few years, GLP-1 receptor agonists have dominated the conversation around weight management. Medicines like Wegovy and Mounjaro have shown genuinely impressive results; I have several friends who feel transformed through the treatment. Demand has been high, reflecting the positive reputation the drugs have created and the underlying need, with an estimated 3.3 million UK adults expected to use weight-loss injections in 2026 alone. But for many people, the weekly injection has remained a sticking point. This month, that changes.
On 11 June 2026, the MHRA approved the UK’s first oral GLP-1 receptor agonist tablet for weight loss: a semaglutide tablet, marketed as Wegovy in pill form. It is a genuinely significant moment — and one that could open up this class of treatment to a much wider group of people.
Like its injectable counterpart, the oral semaglutide tablet works by mimicking GLP-1, a naturally occurring hormone that regulates appetite, digestion, and blood sugar. In simple terms, it helps you feel fuller for longer and reduces the urge to overeat. The tablet is taken once daily, starting at 1.5 mg which can be increased, gradually, to 25 mg.
Clinical trial data are encouraging: the OASIS-4 trial reported a mean weight loss of 13.6% over 64 weeks, with nearly two-thirds of participants losing more than 10% of their body weight — results that seem to be at least equivalent to the injectable version (although the trial).
The shift from injection to tablet is more significant than it might first appear. Needle aversion is common and, for some people, it is simply a dealbreaker, regardless of how effective the medicine might be. A once-daily tablet removes that obstacle entirely.
There are practical advantages too: no sharps bins; no refrigeration requirements for storage on the go; no anxiety about travelling with injectable devices. For people managing busy lives, the simplicity of swallowing a tablet each morning is likely to support better adherence over the long term — and consistency is important when it comes to weight management.
The tablet is approved for adults with a BMI of 30 or above, or those with a BMI between 27 and 30 who have at least one weight-related health condition such as hypertension, type 2 diabetes, or high cholesterol.
The approval by the MHRA is the critical first step, and it happened faster than many had anticipated. As with the injectable formulations, the tablet will initially be available through private prescription, with NHS access subject to ongoing NICE review. The cost of the medication is likely to be similar to the injectable form, which means it will continue to be out of reach for many people and NHS access is likely to be very limited when it comes.
Given the supply pressures that have affected the injectable GLP-1 medicines, availability will be something to watch closely — but the arrival of an oral option has the potential to ease some of the strain on the existing supply chain and make access easier.
The arrival of oral GLP-1 therapy represents a real step forward in making effective, evidence-based treatment more accessible and more appealing to more people. Given the prevalence of weight problems in the UK – two thirds of adults are overweight or obese – this has to be good news.
Useful links:
Teladoc Health offers virtual healthcare services to employers, insurance providers & brokers and banks. Our virtual medical care offering spans Virtual GP, Second Medical Opinion, Virtual Physiotherapy, Virtual Nutrition and more. To get in touch about how our team can assist in offering virtual healthcare services to your team, click here to book a chat.
Continue Reading...
Please enter your email for instant download.
